(NEPH) Nephros - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6406714005
NEPH: Ultrafiltration Systems, Water Filters, Bicarbonate Concentrate
Nephros Inc. (NASDAQ:NEPH), established in 1997, specializes in developing innovative water filtration solutions tailored for medical and commercial sectors. Their product portfolio includes ultrafiltration systems, such as the UltraFilter, designed to eliminate biological contaminants in dialysis centers and hospitals, crucial for preventing waterborne pathogens like Legionella and Pseudomonas. Additionally, they offer consumer-oriented filtration products that enhance water quality and reduce maintenance in various industries.
These filtration systems are integral in diverse settings, including military operations, outdoor recreational areas, and healthcare facilities, ensuring safe water access and preventing infections. Nephros serves multiple markets, including food service and hospitality, where their products improve water taste and reduce equipment wear by minimizing biofilm and particulates.
Over the next three months, NEPH is expected to face a challenging environment. Technically, the stock is in a downtrend, trading below its 200-day moving average at $1.65, with low average volume suggesting limited liquidity. The low ATR indicates modest price fluctuations. Fundamentally, with a market cap of $15.07M and negative RoE, profitability concerns may persist. The stock might experience sideways movement with potential declines, reflecting broader market sentiment towards micro-cap companies in challenging financial positions.
Additional Sources for NEPH Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NEPH Stock Overview
Market Cap in USD | 17m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Household Appliances |
IPO / Inception | 2004-09-21 |
NEPH Stock Ratings
Growth 5y | -77.7% |
Fundamental | 25.3% |
Dividend | 0.0% |
Rel. Strength Industry | -31.6 |
Analysts | 4.5/5 |
Fair Price Momentum | 1.25 USD |
Fair Price DCF | 1.65 USD |
NEPH Dividends
No Dividends PaidNEPH Growth Ratios
Growth Correlation 3m | 16% |
Growth Correlation 12m | -82.2% |
Growth Correlation 5y | -67.2% |
CAGR 5y | -22.89% |
CAGR/Max DD 5y | -0.25 |
Sharpe Ratio 12m | -0.09 |
Alpha | -31.23 |
Beta | 0.38 |
Volatility | 62.58% |
Current Volume | 8.8k |
Average Volume 20d | 8k |
As of March 15, 2025, the stock is trading at USD 1.63 with a total of 8,812 shares traded.
Over the past week, the price has changed by -1.22%, over one month by +7.23%, over three months by +5.15% and over the past year by -24.54%.
Neither. Based on ValueRay Fundamental Analyses, Nephros is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 25.31 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NEPH as of March 2025 is 1.25. This means that NEPH is currently overvalued and has a potential downside of -23.31%.
Nephros has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy NEPH.
- Strong Buy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, NEPH Nephros will be worth about 1.4 in March 2026. The stock is currently trading at 1.63. This means that the stock has a potential downside of -17.18%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 4.8 | 191.4% |
Analysts Target Price | 4.8 | 191.4% |
ValueRay Target Price | 1.4 | -17.2% |